Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA. The listed name for JSPR is Jasper Therapeutics, Inc. Common Stock.
| ID | stock | DATE | BROKER | Avg | SHARE | market | percent | net loss or gain | open | high | Low | Float | avg volume | 52High | 52 Low | Remark | COMPANY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | JSPR | 8/11/2022 | RH | $2.22 | 4.00 | $2.22 | 0.07% | $0.01 | $2.13 | $2.17 | $2.11 | 3156 | 40799 | $18.88 | $1.73 | one week + 5.21 % one months -5.92 % 3months 24.49 % one year 77.64 % | stem cell genetic manipulation |
No comments:
Post a Comment